ArQule up on hope for lung cancer drug revival

(Reuters) - ArQule Inc shares jumped 19 percent on hopes that additional data from a discontinued trial could revive its experimental drug, tivantinib, as a treatment for lung cancer.

via Reuters: Health News Read More Here..